Ovarian Neoplasms Clinical Trial
Official title:
Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
The main purpose of this study is to determine the safety and feasibility of weekly intra-peritoneal administration of Cantrixil to women with persistent or recurrent ovarian cancer, Fallopian tube cancer or primary peritoneal cancer. The study also aims to determine the maximum tolerated dose of Cantrixil in these patients when administered as a monotherapy or a combination therapy.
This study is a progressive design with 2 discrete Parts (Part A: Dose escalation, Part B:
Dose expansion. Cycle 1/Part A is a dose-finding assessment (dose escalation) to establish
the MTD of Cantrixil when administered as a single dose once a week for 3 weeks. Cycle2/Part
A continues with 3 additional weekly doses of Cantrixil as a monotherapy before an assessment
of disease response. In Cycles 3 to 8/Part A, patients will be administered the same once
weekly dose of Cantrixil they tolerated in Cycles 1 and 2 (tolerance defined as no dose
limiting toxicities [DLTs] or unacceptable treatment-related adverse events [AEs]) in
combination with a limited range of standard chemotherapy agent(s), in order to assess the
safety and tolerability of Cantrixil in combination therapy. Standard chemotherapy drugs will
be administered at the standard efficacious doses to maintain optimum benefit of known drug
combinations for patients.
Once the MTD has been determined in Part A, an additional 12 patients will be recruited in an
expansion cohort for Part B. These patients will receive 2 cycles of Cantrixil monotherapy at
the MTD, followed by up to 6 cycles of combination therapy.
Patients enrolled into the respective parts of the study may not receive treatments under
different parts of the protocol.
To accommodate the intraperitoneal administration of Cantrixil, an in-dwelling, closed
catheter or port will be inserted if the patient does not already have one. For
intraperitoneal ports, the minimum period between port placement and the first administration
of Cantrixil must not be shorter than 7 days.
Patients should begin protocol treatment within a maximum of 28 days of enrolment (i.e.,
signing of consent form).
Patients will start at Dose Level 0 which is calculated to be the human equivalent of 10% of
the STD10 dose in rats (dose is 1/10 the severely toxic dose in 10% of rats tested). Dose
levels -1 and -2 will only be activated if there are 2 DLTs at the Dose Level 0 and -1,
respectively. Single patient cohorts will be treated with increasing doses of Cantrixil until
an AE is observed that meets the definition of a Dose Limiting Toxicity (DLT) or, in the
opinion of the Data Safety Monitoring Committee (DSMC) and the Investigator, is causally
related to study treatment and warrants observing additional patients at this dose level; at
this point the study will revert to a 3+3 rules based dose escalation study. Once the study
enters a 3+3 rules-based design, the study will not revert back to single patient cohorts.
If any unacceptable treatment-related AE or DLT is observed in any cycle, patients may be
dose reduced to the next lower dose level of Cantrixil for subsequent doses of therapy. If a
second unacceptable treatment-related AE or DLT is observed during any cycle within the same
patient, treatment for the patient with Cantrixil will be discontinued. Investigators may
continue with the standard chemotherapy at their discretion and if it is considered safe and
in the patient's best interest.
If any of the following unacceptable treatment-related AEs or DLTs are observed and unless
clearly unrelated to study treatment (e.g., disease progression), treatment at the allocated
Cantrixil dose will be discontinued and dose escalation may be considered:
- Hematologic toxicity
- Grade 4 neutropenia, lasting at least 5 days,
- Grade 3 or Grade 4 neutropenia associated with fever >38.5°C,
- Grade 4 thrombocytopenia lasting at least 5 days,
- Grade 3 thrombocytopenia associated with severe bleeding in the opinion of the
Investigator,
- Dose delay of ≥3 weeks due to failure to recover counts.
- Any Common Terminology Criteria for Adverse Events (CTCCTCAE) version 4.03 Grade 3 or
Grade 4 non haematological toxicity except:
- Alopecia
- Grade 3 abdominal pain deemed related to the port or catheter as determined by the
treating physician
- Grade 3 anorexia
- Grade 3 fatigue
- Grade 3 nausea and/or vomiting, or diarrhoea, lasting ≤48 hours with or without
maximal medical management.
- Grade 3 dehydration as a result of nausea and vomiting
- Grade 3 constipation
- Grade 3 metabolic abnormalities [hypokalaemia, hypomagnesemia, hypocalcaemia,
hypophosphatemia]) that recovers to Grade 1 or less within 48 hours with or without
medical management o• Other serious adverse events (SAEs) which, in the opinion of
the treating Investigator, are related to investigational product and necessitate
temporary or permanent cessation of administration o• Treatment delays of ≥3 weeks
due to any treatment-related non-haematological toxicity will constitute a DLT All
patients who discontinued from the study (i.e. are now Off Therapy/ End of Therapy)
treatment will progress to follow-up unless the patient withdraws consent.
The initiation of each new cycle of Cantrixil will be at the discretion of the Investigator
and will depend on the potential or measurable benefit to the patient assuming continued
tolerability and adequate organ function.
Cantrixil treatment will be stopped due to RECIST version 1.1 defined disease progression
observed after at least 4 cycles of therapy, recurrence of unacceptable toxicity after 1
Cantrixil dose reduction or patient consent withdrawal. Note that patients with progressive
disease at the end of 2 cycles of Cantrixil monotherapy will not be taken off therapy if
Cantrixil has been well tolerated. Pre-clinical data would suggest that the maximum benefit
from Cantrixil will be realised as a combination therapy, hence all patients will have the
opportunity to continue receiving Cantrixil as a combination therapy. Additionally, patients
receiving combination therapy that are observed to have progressive disease as identified by
RECIST version 1.1 criteria but who, in the opinion of the Investigator, continued to derive
clinical benefit may continue Cantrixil treatment. Patients may also be discontinued from
study treatment if the Investigator considers continuing therapy is not in the patient's best
interest. All patients discontinued from study treatment will progress to follow-up unless
the patient withdraws consent.
Tumour assessment via radiological imaging will be conducted during screening and every 6
weeks after the start of therapy, i.e. at the end of monotherapy and then after every 2
cycles of combination therapy. Either contrast-enhanced magnetic resonance imaging (MRI) or
contrast-enhanced computed tomography (CT) may be used, but once a modality is used at
baseline this must be used consistently for that patient throughout their participation on
the study. Other imaging is not mandatory, but may be performed if clinically indicated.
Adverse events will be monitored for the duration of the study from the time of informed
consent. Blood samples will be collected weekly for standard safety testing, or more
frequently if clinically relevant, during the study. Additional volumes of blood will be
collected before and after administration of Cantrixil for PK analysis (4 mL per time point
as per the proposed PK schedule and for any exploratory studies (at baseline, end of Cycle 2
and end of treatment, 15 to 20 mL at each time-point).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03648489 -
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
|
Phase 2 | |
Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
Completed |
NCT02569983 -
The SOCQER-2 Study Surgery in Ovarian Cancer - Quality of Life Evaluation Research
|
||
Terminated |
NCT02055690 -
PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02243059 -
Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer
|
Phase 4 | |
Completed |
NCT01719926 -
Phase I Platinum Based Chemotherapy Plus Indomethacin
|
Phase 1 | |
Completed |
NCT00415181 -
Pharmacogenomics of Paclitaxel in Ovarian Cancer
|
N/A | |
Completed |
NCT00243685 -
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT01789229 -
Establishment of a Tumor Bank for Tissue Samples
|
||
Completed |
NCT00772863 -
Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer
|
Phase 2 | |
Completed |
NCT00069160 -
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
|
Phase 2 | |
Completed |
NCT00046800 -
Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
|
Phase 2 | |
Completed |
NCT00035100 -
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
|
Phase 2 | |
Terminated |
NCT00034372 -
Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma
|
Phase 2 | |
Completed |
NCT00001272 -
A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients
|
Phase 1 | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
|
Phase 1/Phase 2 | |
Completed |
NCT02227654 -
Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors
|
N/A | |
Not yet recruiting |
NCT04055038 -
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
|
Phase 2/Phase 3 |